GLSI greenwichlifesciences.com: Business Value to Revenue

Greenwich LifeSciences Inc. (GLSI) - corporate logo

The EV/Sales multiple on GURU.Markets in this chart reflects the strategy of Greenwich LifeSciences (GLSI) to capture the market via Flamingo-01, where 0.00 determines the current status of the parameter. High capital expenditures for Phase III vaccine trials create financial pressure in the absence of revenue. However, the 100% clinical efficacy of the GP2 drug could establish a new standard for the prevention of breast cancer recurrence.

Greenwich LifeSciences, Inc. (GLSI): EV/Sales Multiple from 11/23/2025 to 11/20/2026

Financial and market metric breakdowns for Greenwich LifeSciences Inc (GLSI)

Fundamental company valuation:GLSI (Greenwich LifeSciences)
Finished products of Greenwich LifeSciences, Inc

For the biotech firm Greenwich LifeSciences (GLSI), whose assets are limited to laboratories and a lack of manufacturing plants, this indicator is critically important. It compares the total enterprise value of the business with annual turnover, excluding the impact of leverage. The metric is calculated as the ratio of EV to revenue, stripped of debt obligations. By analyzing the enterprise value-to-revenue level, an investor can identify artificial inflation of capitalization. Abnormal stability of the line signals risks of reporting manipulation.